培美曲塞
医学
卡铂
腹膜间皮瘤
BAP1型
无容量
吉西他滨
恶性肿瘤
间皮瘤
肿瘤科
化疗
内科学
病理
免疫疗法
癌症
顺铂
作者
Tobias Maharaj,Chris Steele,Hajnalka Győrffy,Siobhan Nicholson,Łukasz Milewski,John Aird,Jürgen Mulsow,Darren Cowzer
出处
期刊:Case Reports
[BMJ]
日期:2025-07-01
卷期号:18 (7): e264825-e264825
标识
DOI:10.1136/bcr-2025-264825
摘要
Malignant peritoneal mesothelioma (MPeM) is a rare malignancy involving the abdominal peritoneum typically presenting after middle age with little known of survival in the young. We present a patient in his 20’s with no known asbestos exposure diagnosed with epithelioid-type MPeM and loss of BAP1 gene expression. Our patient demonstrated diffuse unresectable disease at presentation. He had a poor response to first-line treatment carboplatin-pemetrexed chemotherapy followed by ipilimumab plus nivolumab immunotherapy in the second line and carboplatin plus gemcitabine in the third line. Our patient subsequently died 10 months after diagnosis. Despite our patient having favourable prognostic markers such as BAP1 loss in epithelioid subtype mesothelioma, our patient had poor treatment response and survival, highlighting the heterogeneity within this subgroup and likely alternative underlying factors impacting outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI